Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plonmarlimab for Rheumatic Disease-Associated HLH (MAS)
NCT07034209Phase 2Completed
- Sponsor
- TJ Biopharma
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of plonmarlimab in macrophage activation syndrome (MAS), hemophagocytic lymphohistiocytosis (HLH), sponsored by TJ Biopharma. Started Apr 2023; status: completed.
02
Drugs
plonmarlimab
03
Conditions
macrophage activation syndrome (MAS)hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT07034209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034209.